Legend Biotech Corporation (LEGN) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Legend Biotech Corporation (LEGN) posted $1.03B in revenue for fiscal 2025 (up 64.0% year over year), with a net loss of $296.80M, and has compounded revenue about 106.4%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Legend Biotech Corporation
Legend Biotech Corporation has grown revenue from $117.00M to $1.03B over the last 4 fiscal years, compounding about 106.4% a year. The most recent year was up 64%, so growth has cooled from its longer-run pace.
Net margin sits at -28.8%, down 0.6 points year over year on a 60.3% gross margin. It carries about $319.10M of total debt.
The one thing worth a second look in the filings is receivables growing faster than sales.
Synthesised from Legend Biotech Corporation's SEC filings — descriptive, not advice. Ask the analyst your own question →
Legend Biotech Corporation revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $117.00M | $285.10M | $627.30M | $1.03B |
| Gross profit | $51.64M | $140.90M | $392.70M | $620.80M |
| Net income | $-446.35M | $-518.30M | $-177.00M | $-296.80M |
| Net margin | -381.5% | -181.8% | -28.2% | -28.8% |
Source: Legend Biotech Corporation SEC filings (10-K).
Legend Biotech Corporation: 4 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Receivables growing faster than salesAccounts receivable rose 100.1% while revenue rose 64.0% in the latest year — a gap that can signal looser credit terms or pulled-forward sales. Worth checking days-sales-outstanding.
- Share count rising (dilution)Shares outstanding grew 12.0% over 3 years (330.1M → 369.9M) — existing holders' stakes are being diluted.
- Debt with negative operating cash flowCarries $638.2M of debt while last year's operating cash flow was negative ($-100.2M).
- Currently unprofitableThe latest fiscal year was a net loss (net margin -28.8%).
Explore 4 years of Legend Biotech Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track LEGN in your portfolio →
Legend Biotech Corporation financial history by metric
About Legend Biotech Corporation
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Legend Biotech Corporation — frequently asked questions
What is Legend Biotech Corporation's revenue?
Legend Biotech Corporation (LEGN) reported revenue of $1.03B for fiscal year 2025, up 64.0% from the prior year, according to its SEC filings.
Is Legend Biotech Corporation profitable?
No — LEGN reported a net loss of $-296.80M in fiscal 2025.
What is LEGN's P/E ratio?
Legend Biotech Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Legend Biotech Corporation growing?
LEGN's revenue grew at roughly 106.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Legend Biotech Corporation have?
As of fiscal year 2025, LEGN carried roughly $319.10M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Legend Biotech Corporation's gross margin?
LEGN's gross margin was 60.3% in fiscal 2025 — gross profit of $620.80M on revenue of $1.03B.
What is Legend Biotech Corporation's market cap?
Legend Biotech Corporation (LEGN) has a market capitalization of about $6.55B, based on the latest data in our nightly-refreshed cache.
When does Legend Biotech Corporation's fiscal year end?
LEGN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Legend Biotech Corporation's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.